The Role of Natural Killer (NK) Cells and NK Cell Receptor Polymorphisms in the Assessment of HIV-1 Neutralization

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Apr 18

PMID 22509241

Citations 17

Authors

Bruce K Brown

Lindsay Wieczorek

Gustavo Kijak

Kara Lombardi

Jeffrey Currier

Maggie Wesberry

John C Kappes

Viseth Ngauy

Mary Marovich

Nelson Michael

Christina Ochsenbauer

David C Montefiori

Victoria R Polonis

Affiliations

Soon will be listed here.

Abstract

The importance of innate immune cells in HIV-1 pathogenesis and protection has been highlighted by the role of natural killer (NK) cells in the containment of viral replication. Use of peripheral blood mononuclear cells (PBMC) in immunologic studies provides both HIV-1 target cells (ie. CD4+ T cells), as well as anti-HIV-1 effector cells, such as NK cells. In this study, NK and other immune cell populations were analyzed in HIV-negative donor PBMC for an impact on the anti-HIV activity of polyclonal and monoclonal antibodies. NK cell percentages were significantly higher in donor PBMC that supported lower levels of viral replication. While the percentage of NK cells was not directly associated with neutralization titers, NK cell-depletion significantly diminished the antiviral antibody activity by up to three logs, and polymorphisms in NK killer immunoglobulin receptor (KIR) and FcγRIIIa alleles appear to be associated with this affect. These findings demonstrate that NK cells and NK cell receptor polymorphisms may influence assessment of traditional HIV-1 neutralization in a platform where antibody is continuously present. This format appears to simultaneously assess conventional entry inhibition (neutralization) and non-neutralizing antibody-dependent HIV inhibition, which may provide the opportunity to delineate the dominant antibody function(s) in polyclonal vaccine responses.

Citing Articles

Distinctive Responses in an In Vitro Human Dendritic Cell-Based System upon Stimulation with Different Influenza Vaccine Formulations.

Tapia-Calle G, Stoel M, De Vries-Idema J, Huckriede A Vaccines (Basel). 2017; 5(3).

PMID: 28792466 PMC: 5620552. DOI: 10.3390/vaccines5030021.

Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers.

Joachim A, Munseri P, Nilsson C, Bakari M, Aboud S, Lyamuya E AIDS Res Hum Retroviruses. 2016; 33(8):880-888.

PMID: 28027665 PMC: 5564012. DOI: 10.1089/AID.2016.0251.

Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.

OConnell R, Excler J, Polonis V, Ratto-Kim S, Cox J, Jagodzinski L J Infect Dis. 2016; 213(12):1946-54.

PMID: 26908741 PMC: 4878724. DOI: 10.1093/infdis/jiw059.

The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.

Seay K, Khajoueinejad N, Zheng J, Kiser P, Ochsenbauer C, Kappes J J Virol. 2015; 89(18):9559-70.

PMID: 26157126 PMC: 4542360. DOI: 10.1128/JVI.01326-15.

Optimized Replicating Renilla Luciferase Reporter HIV-1 Utilizing Novel Internal Ribosome Entry Site Elements for Native Nef Expression and Function.

Alberti M, Jones J, Miglietta R, Ding H, Bakshi R, Edmonds T AIDS Res Hum Retroviruses. 2015; 31(12):1278-96.

PMID: 26101895 PMC: 4663642. DOI: 10.1089/aid.2015.0074.

References

Alter G, Altfeld M . NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. J Intern Med. 2008; 265(1):29-42. PMC: 2842208. DOI: 10.1111/j.1365-2796.2008.02045.x. View

Robert-Guroff M, Brown M, Gallo R . HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature. 1985; 316(6023):72-4. DOI: 10.1038/316072a0. View

Alter G, Rihn S, Walter K, Nolting A, Martin M, Rosenberg E . HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J Virol. 2009; 83(13):6798-805. PMC: 2698561. DOI: 10.1128/JVI.00256-09. View

Spear G, Sullivan B, Landay A, Lint T . Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J Virol. 1990; 64(12):5869-73. PMC: 248749. DOI: 10.1128/JVI.64.12.5869-5873.1990. View

Koup R, Graham B, Douek D . The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nat Rev Immunol. 2010; 11(1):65-70. DOI: 10.1038/nri2890. View

Carrington M, Martin M, van Bergen J . KIR-HLA intercourse in HIV disease. Trends Microbiol. 2008; 16(12):620-7. PMC: 3463869. DOI: 10.1016/j.tim.2008.09.002. View

Barbour J, Sriram U, Caillier S, Levy J, Hecht F, Oksenberg J . Synergy or independence? Deciphering the interaction of HLA Class I and NK cell KIR alleles in early HIV-1 disease progression. PLoS Pathog. 2007; 3(4):e43. PMC: 1853116. DOI: 10.1371/journal.ppat.0030043. View

Nishimura Y, Igarashi T, Haigwood N, Sadjadpour R, Donau O, Buckler C . Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci U S A. 2003; 100(25):15131-6. PMC: 299920. DOI: 10.1073/pnas.2436476100. View

Kim J, Rerks-Ngarm S, Excler J, Michael N . HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS. 2010; 5(5):428-34. PMC: 2990218. DOI: 10.1097/COH.0b013e32833d17ac. View

10.

Forthal D, Landucci G, Cole K, Marthas M, Becerra J, Van Rompay K . Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol. 2006; 80(18):9217-25. PMC: 1563916. DOI: 10.1128/JVI.02746-05. View

11.

Forthal D, Landucci G, Daar E . Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol. 2001; 75(15):6953-61. PMC: 114423. DOI: 10.1128/JVI.75.15.6953-6961.2001. View

12.

Betts M, Nason M, West S, De Rosa S, Migueles S, Abraham J . HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006; 107(12):4781-9. PMC: 1895811. DOI: 10.1182/blood-2005-12-4818. View

13.

Pitisuttithum P, Berman P, Phonrat B, Suntharasamai P, Raktham S, Srisuwanvilai L . Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr. 2004; 37(1):1160-5. DOI: 10.1097/01.qai.0000136091.72955.4b. View

14.

Pillay V, Gan H, Scott A . Antibodies in oncology. N Biotechnol. 2011; 28(5):518-29. DOI: 10.1016/j.nbt.2011.03.021. View

15.

Fehniger T, Herbein G, Yu H, Para M, Bernstein Z, OBRIEN W . Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. J Immunol. 1998; 161(11):6433-8. View

16.

Matyas G, Wieczorek L, Bansal D, Chenine A, Sanders-Buell E, Tovanabutra S . Inhibition of HIV-1 infection of peripheral blood mononuclear cells by a monoclonal antibody that binds to phosphoinositides and induces secretion of β-chemokines. Biochem Biophys Res Commun. 2010; 402(4):808-12. PMC: 7173129. DOI: 10.1016/j.bbrc.2010.10.124. View

17.

Darden J, Polonis V, Desouza M, Chantakulkij S, Brown A, Birx D . A flow cytometric method for measuring neutralization of HIV-1 subtype B and E primary isolates. Cytometry. 2000; 40(2):141-50. View

18.

Baba T, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S . Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000; 6(2):200-6. DOI: 10.1038/72309. View

19.

Ferrari G, Korber B, Goonetilleke N, Liu M, Turnbull E, Salazar-Gonzalez J . Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS Pathog. 2011; 7(2):e1001273. PMC: 3037354. DOI: 10.1371/journal.ppat.1001273. View

20.

Holl V, Peressin M, Decoville T, Schmidt S, Zolla-Pazner S, Aubertin A . Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol. 2006; 80(12):6177-81. PMC: 1472578. DOI: 10.1128/JVI.02625-05. View